CYP 0.00% 27.0¢ cynata therapeutics limited

No, I appreciate that the excerpts you posted are from CYP's...

  1. 658 Posts.
    lightbulb Created with Sketch. 161
    No, I appreciate that the excerpts you posted are from CYP's corporate governance ann. So it is specific to CYP, but the issue of disclosure under placements and information asymmetry isn't. That CYP corporate governance statement ann is much like clinical trial result anns and an issue I have read you highlight previously - the ann is a summary/generalisation that glosses over some nuance and specifics. In this case it's a general statement of principles, but if you delve into the specifics it contains exceptions. That is a common issue, not just a CYP issue.

    CYP's full corporate governance disclosure is here: https://cynata.com/corporate-governance The Continuous Disclosure section alone is a 17 page pdf and notes the exception I posted from the Corporations Regulations in 2.2
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.